From Patient to Problem Solver

• by Helen Bristow

• September 23, 2026

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

• by Kathryn Wighton

• September 21, 2026

• 2 min

ECP 2026: Is HPV-Specific Testing Optimized in Throat Cancer?

Cost and turnaround times are a potential challenge to standardization of testing and optimization of patient pathways

• September 14, 2026

• 2 min

Educators weigh how to use AI without losing critical thinking

Greater productivity is not necessarily indicative of greater knowledge.

• by Julia Cipriano, MS, CMPP

• September 10, 2026

• 8 min